↩ back to the box














#outlook a { padding:0; }

body { margin:0;padding:0;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%; }

table, td { border-collapse:collapse;mso-table-lspace:0pt;mso-table-rspace:0pt; }

img { border:0;height:auto;line-height:100%; outline:none;text-decoration:none;-ms-interpolation-mode:bicubic; }

p { display:block;margin:13px 0; }



@import url(https://fonts.googleapis.com/css?family=Roboto:300,400,500,700);

@media only screen and (min-width:480px) {

.mj-column-per-100 { width:100% !important; max-width: 100%; }

.mj-column-per-70 { width:70% !important; max-width: 70%; }

.mj-column-per-30 { width:30% !important; max-width: 30%; }

}

@media only screen and (max-width:480px) {

table.mj-full-width-mobile { width: 100% !important; }

td.mj-full-width-mobile { width: auto !important; }

}

html, body {

-webkit-font-smoothing: antialiased;

}

a {

color: inherit;

}

.section-wrapper {

box-shadow: 0px 0.5px 1px rgba(132, 135, 154, 0.2),

0px 2px 43px rgba(132, 135, 154, 0.05)

}

.portfolio-stat {

display: block;

width: 100%;

margin-bottom: 3px;

}

.slash-separator {

display: inline-block;

padding: 0 8px;

color: #D0CFD9;

}

.portfolio-table thead {

background-color: #F9F9FA;

border-bottom: 1px solid #F3F3F5;

}

.portfolio-table tr th,

.portfolio-table tr td {

padding: 8px 10px;

}

.portfolio-table thead th {

color: #86859D;

}

.portfolio-table > table {

border: 1px solid #F3F3F5 !important;

border-radius: 5px;

}

.portfolio-table tbody tr:nth-child(even) td {

background-color: #FBFBFC;

}

.positive-text { color: #47B877; }

.negative-text { color: #F63B40; }

.section--article {

padding: 10px 25px;

}



.section--article > table {

display: block;

overflow: hidden;

border-radius: 5px;

border: 1px solid #F3F3F5;

}

.article-title a,

.article-perex a {

text-decoration: none !important;

}



.events-table > table {

border: 1px solid #f3f3f5 !important;

}

.events-table tbody tr:nth-child(even) td {

background-color: #FBFBFC;

}



.index-performance {

display: inline-block;

background-color: #F3F3F5;

font-weight: 500;

padding: 6px 14px;

border-radius: 50px;

margin-right: 10px;

margin-bottom: 10px;

}

.generic-table > table {

border: 1px solid #f3f3f5 !important;

}

.generic-table thead {

border-bottom: 1px solid #F3F3F5;

}

.generic-table thead th,

.generic-table thead td {

background-color: #F9F9FA;

color: #86859D;

text-align: left;

}

.generic-table th,

.generic-table td {

padding: 8px 10px;

}

.generic-table tbody tr:nth-child(even) td {

background-color: #FBFBFC;

}

.link-nostyle { color: inherit; text-decoration: none }

.nowrap { white-space: nowrap !important; }



@media (max-width: 480px) {

.section-wrapper > table > tbody > tr > td { padding: 0 !important }

.mj-button table { width: 100%; }



thead th { white-space: nowrap }

td, th { font-size: 11px; }

td { font-weight: normal; }

td small, th small { font-size: 9px }

.hidden-mobile { display: none !important; }

}







U.S. stocks rose on Monday as Nasdaq rebounded from its biggest one-week decline since March and Oracle confirmed a partnership with ByteDance. source Nvidia to buy fellow chipmaker Arm for $40 billion from SoftBank. For SoftBank, the sale marks an early exit from the UK-based chip designer, just four years after the $32 billion acquisition. source Gilead to acquire biotech drugmaker Immunomedics for $21 billion to strengthen its cancer treatment portfolio. Shares of Immunomedics have surged more than 100%. source













Here's your daily digest of the most important events in the financial markets. The more you use wallmine, the better this email becomes.

















Today's markets



S&P 500 +1.74% NASDAQ +2.33% Russell 2000 +1.89%





U.S. stocks rose on Monday as Nasdaq rebounded from its biggest one-week decline since March and Oracle confirmed a partnership with ByteDance. sourceNvidia to buy fellow chipmaker Arm for $40 billion from SoftBank. For SoftBank, the sale marks an early exit from the UK-based chip designer, just four years after the $32 billion acquisition. sourceGilead to acquire biotech drugmaker Immunomedics for $21 billion to strengthen its cancer treatment portfolio. Shares of Immunomedics have surged more than 100%. source





















Today's top stories

Based on your activity on wallmine











Britain to scrutinise Arm takeover

Britain's government will scrutinise a deal by Nvidia Corp NVDA.O to buy British chip designer Arm inc...













ByteDance picks Oracle as winning bidder for TikTok's U.S. operations - source

China's ByteDance has picked a consortium led by Oracle Corp ORCL.N for a deal for the U.S. operations...













ByteDance picks Oracle as partner to try to save TikTok U.S.: sources

Oracle beat Microsoft in the battle for the U.S. arm of TikTok with a deal structured as a partnership...













Trump rallies supporters in Nevada, seeks to overcome Biden lead in the state

Republican President Donald Trump rallied his backers in Nevada on Saturday in a bid to drum up suppor...













Delta pledges loyalty program to raise $6.5 billion

Delta Air Lines DAL.N said on Monday it is seeking to raise $6.5 billion through new bonds and loans b...













Amazon to hire 100,000 more workers in its latest job spree this year

Amazon.com Inc AMZN.O on Monday said it is recruiting 100,000 more workers - the fourth hiring spree i...





















Today's moves

 





Symbol

% today

% 1 month

% 3 months









TSLA $400.14



+7.36%

+21.20%

+113.91%







NVDA $516.65



+6.18%

+11.69%

+44.60%







ORCL $60.17



+5.56%

+11.01%

+16.02%







ZM $398.81



+4.13%

+62.84%

+81.67%







ADBE $487.81



+3.49%

+8.98%

+19.99%

























Upcoming Events









September 14, 2020

KO ex-dividend date / MRK ex-dividend date / TMO ex-dividend date











September 15, 2020

ADBE earnings























Got feedback on how to make this email better? Please, let us know!

Generated on 14 September 2020 at 11:41am EST.















wallmine.com, 3501 Jack Northrop Ave, Suite #XM642, Hawthorne, CA 90250, USAUnsubscribe from these daily e-mails and we only send you a quick summary of your account once a week, every Tuesday morning, going forward. Alternatively, you can also opt-out from both daily and weekly e-mails or remove your e-mail from all of our communications.




















Warning: the message above can be a phishing scam. See: legal notes